A Multicentre, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Fondaparinux Versus Low Molecular Weight Heparin (Nadroparin) in Patients Requiring Rigid or Semi-Rigid Immobilization for at Least 21 Days and up to 45 Days Because of Isolated Non-Surgical Below-Knee Injury.

Trial Profile

A Multicentre, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Fondaparinux Versus Low Molecular Weight Heparin (Nadroparin) in Patients Requiring Rigid or Semi-Rigid Immobilization for at Least 21 Days and up to 45 Days Because of Isolated Non-Surgical Below-Knee Injury.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2014

At a glance

  • Drugs Fondaparinux sodium (Primary) ; Nadroparin calcium (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism; Venous thrombosis
  • Focus Therapeutic Use
  • Acronyms FONDACAST
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 Feb 2012 Status changed from recruiting to completed.
    • 02 Apr 2010 Additional trial location [Russia] identified as reported by ClinicalTrials.gov.
    • 11 Jul 2009 Lead investigator identified; stated in an abstract (22nd Congress of the International Society on Thrombosis and Haemostasis: 1182 abstr. PC-023, 11 Jul 2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top